Components of RAS, such as AT1R and ACE, are abnormally expressed in various malignancies, ranging from CC-RCC to triple-negative breast cancer (TNBC), and their expression correlates with poor patient outcomes. This evidence concerns the gene ACE and renal cell carcinoma.